Literature DB >> 3888243

Reduced survival with radiotherapy and razoxane compared with radiotherapy alone for inoperable lung cancer in a randomised double-blind trial.

C E Newman, R Cox, C H Ford, J R Johnson, D R Jones, M Wheaton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3888243      PMCID: PMC1977056          DOI: 10.1038/bjc.1985.109

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  5 in total

1.  On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial.

Authors:  L S Freedman; S J White
Journal:  Biometrics       Date:  1976-09       Impact factor: 2.571

2.  Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer.

Authors:  M T Bakowski; E Macdonald; R F Mould; P Cawte; J Sloggem; A Barrett; V Dalley; K A Newton; G Westbury; S E James; K Hellmann
Journal:  Int J Radiat Oncol Biol Phys       Date:  1978 Jan-Feb       Impact factor: 7.038

3.  The analysis of a sequential clinical trial for the comparison of two lung cancer treatments.

Authors:  J Whitehead; D R Jones; S H Ellis
Journal:  Stat Med       Date:  1983 Apr-Jun       Impact factor: 2.373

4.  ICRF 159 plus radiation versus radiation therapy alone in cervical carcinoma. A double-blind study.

Authors:  C Belloni; C Mangioni; G Bortolozzi; S Carinelli; M D'Incalci; A Maggioni; L Morasca
Journal:  Oncology       Date:  1983       Impact factor: 2.935

5.  The design of a sequential clinical trial for the comparison of two lung cancer treatments.

Authors:  D R Jones; C E Newman; J Whitehead
Journal:  Stat Med       Date:  1982 Jan-Mar       Impact factor: 2.373

  5 in total
  1 in total

1.  Interim analyses and stopping rules in cancer clinical trials.

Authors:  J Whitehead
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.